Have a chat to help others through lonelinessLooking back over the past 18 months, the Joni Mitchell lyric ‘you don’t know what you’ve got til it’s Share XHave a chat to help others through lonelinesshttps://pharmaphorum.com/views-and-analysis/have-a-chat-to-help-others-through-loneliness/
New Cell & Gene Therapy Collective seeks to boost UK adoptionThe UK has been a global leader in introducing cell and gene therapies that can potentially transform the Share XNew Cell & Gene Therapy Collective seeks to boost UK adoptionhttps://pharmaphorum.com/views-and-analysis/new-cell-gene-therapy-collective-seeks-to-boost-uk-adoption/
BMS launches digital Advocacy Exchange for patient groups affected by COVID-19Bristol Myers-Squibb and digital health firm GRYT Health have teamed up to develop an ‘Advocacy Exchange’ virtual platform Share XBMS launches digital Advocacy Exchange for patient groups affected by COVID-19https://pharmaphorum.com/views-analysis-digital/bms-launches-digital-advocacy-exchange-for-patient-groups-affected-by-covid-19/
ASCO 2020 round-up: Virtual conference still delivers the dramaASCO may have been virtual this year because of the COVID-19 pandemic, but there were still some show-stopping Share XASCO 2020 round-up: Virtual conference still delivers the dramahttps://pharmaphorum.com/views-analysis-oncology/asco-2020-round-up-virtual-conference-still-delivers-the-drama/
The future of real world evidenceIncreasing interest in real-world evidence (RWE) across all stakeholder groups has the industry buzzing about its current role Share XThe future of real world evidencehttps://pharmaphorum.com/r-d/views-analysis-r-d/future-real-world-evidence-rwe/
BMS plans another tack as EU regulators knock back lung cancer comboBristol-Myers Squibb has withdrawn a European filing of its immunotherapy combination of Opdivo and Yervoy in first line Share XBMS plans another tack as EU regulators knock back lung cancer combohttps://pharmaphorum.com/news/bms-withdraws-eu-filing-for-opdivoyervoy-in-nsclc/
2019: the year of the pharma mega-merger2019 will be remembered as the year of the pharma mega-merger. Richard Staines looks back at a year Share X2019: the year of the pharma mega-mergerhttps://pharmaphorum.com/views-and-analysis/2019-the-year-of-the-pharma-mega-merger/
BMS has another Opdivo setback after liver cancer trial failureBristol-Myers Squibb’s cancer immunotherapy Opdivo has suffered another setback after it failed to improve on standard care in Share XBMS has another Opdivo setback after liver cancer trial failurehttps://pharmaphorum.com/news/bms-has-another-opdivo-setback-after-liver-cancer-trial-failure/
BMS reveals its post-Celgene takeover management teamBristol-Myers Squibb has announced its new-look leadership after the Celgene takeover goes through, and it reveals a mixed Share XBMS reveals its post-Celgene takeover management teamhttps://pharmaphorum.com/news/bms-post-celgene-takeover-management-team/
